SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of SL-11047 in
treating patients with relapsed or refractory lymphoma.